quinazolines has been researched along with Parkinson Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, MV; Davies, SB; Fiolek, TJ; Magyar, CL; Mosey, RA; Savich, CJ; Tepe, JJ; Wall, TJ | 1 |
| Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ | 1 |
| Gao, H; Jiang, S; Mao, J; Wang, D; Yang, X | 1 |
| Avale, ME; Bernardi, MA; Bordone, MP; Damianich, A; Ferrario, JE; Gershanik, OS; Gomez, G; Hanger, DP; Isaja, L; Sanz-Blasco, S; Taravini, IR | 1 |
| Burbulla, LF; Jeon, S; Jiang, W; Krainc, D; Oevel, K; Silverman, RB; Ysselstein, D; Zheng, J | 1 |
| Chen, L; Krainc, D; Schwake, M; Silverman, RB; Zheng, J | 1 |
| Bhatnagar, SP; Laddha, SS | 1 |
| Agid, Y; Cash, R; Lasbennes, F; Sercombe, R; Seylaz, J | 1 |
8 other study(ies) available for quinazolines and Parkinson Disease
| Article | Year |
|---|---|
Dihydroquinazolines enhance 20S proteasome activity and induce degradation of α-synuclein, an intrinsically disordered protein associated with neurodegeneration.
Topics: alpha-Synuclein; Dose-Response Relationship, Drug; Humans; Intrinsically Disordered Proteins; Molecular Structure; Parkinson Disease; Proteasome Endopeptidase Complex; Quinazolines; Structure-Activity Relationship | 2021 |
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Denmark; Doxazosin; Female; Follow-Up Studies; Glycolysis; Humans; Male; Middle Aged; Parkinson Disease; Prazosin; Quinazolines; Registries; Risk Factors; Tamsulosin; United States | 2021 |
NF‑κB is negatively associated with Nurr1 to reduce the inflammatory response in Parkinson's disease.
Topics: Animals; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; PC12 Cells; Quinazolines; Rats; Synucleins; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2021 |
The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Topics: Animals; Benzodioxoles; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Movement; Neostriatum; Parkinson Disease; Phosphorylation; Protein Subunits; Proto-Oncogene Proteins c-fyn; Quinazolines; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2018 |
Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.
Topics: Dopaminergic Neurons; Enzyme Activators; Enzyme Inhibitors; Gaucher Disease; Glucosylceramidase; Humans; Methylation; Parkinson Disease; Quinazolines; Structure-Activity Relationship | 2019 |
Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase Modulators.
Topics: Cell Line; Drug Design; Enzyme Stability; Gaucher Disease; Glucosylceramidase; Humans; Parkinson Disease; Quinazolines | 2016 |
A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Child, Preschool; Cyclic Nucleotide Phosphodiesterases, Type 1; Drug Evaluation, Preclinical; Edema; Humans; Parkinson Disease; Phosphodiesterase Inhibitors; Quinazolines; Rats; Stomach Ulcer; Structure-Activity Relationship | 2009 |
Adrenergic receptors on cerebral microvessels in control and parkinsonian subjects.
Topics: Aged; Alprenolol; Capillaries; Cerebrovascular Circulation; Clonidine; Dihydroalprenolol; Humans; Kinetics; Parkinson Disease; Prazosin; Quinazolines; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Reference Values | 1985 |